Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Imugene ( (AU:IMU) ) is now available.
Imugene Limited has announced the application for the quotation of 68,236,857 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective July 24, 2025. This move is part of previously announced transactions and reflects the company’s ongoing efforts to strengthen its financial position and support its strategic initiatives in the biotechnology sector.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited operates in the biotechnology industry, focusing on the development of immuno-oncology therapies. The company is dedicated to advancing innovative cancer treatments that harness the body’s immune system to target and eradicate cancer cells.
Average Trading Volume: 688,967
Technical Sentiment Signal: Sell
Current Market Cap: A$70.31M
Learn more about IMU stock on TipRanks’ Stock Analysis page.